Assessing the biomarker potential of plasma ITPKB expression levels in Alzheimer's Disease

Current literature points out that ITPKB contributes to AD pathogenesis, particularly through neuroinflammation and tau phosphorylation. Based on this background, we hypothesized that ITPKB could serve as a diagnostic biomarker for AD. However, our preliminary results indicate that ITPKB is downregulated in AD plasma samples compared to controls across all disease stages. Moreover, ITPKB expression levels showed a positive correlation with MMSE scores, suggesting a potential alternative role in AD progression. Once these results are validated with further studies and underlying mechanisms are identified, ITPKB expression can be regarded as a potential plasma biomarker in AD.